Isracann Biosciences Inc. (OTCMKTS:ISCNF) Short Interest Down 96.5% in January
Isracann Biosciences Inc. (OTCMKTS:ISCNF – Get Rating) was the recipient of a significant drop in short interest in the month of January. As of January 15th, there was short interest totalling 3,300
Isracann Biosciences Provides Bi-Weekly Default Status Report
VANCOUVER, British Columbia, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the "Company") announces that further to its news release dated Sept
Isracann Biosciences Announces Delay in Filing Annual Financial Statements
VANCOUVER, British Columbia, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the "Company") announces that the filing of its audited annual fina
Isracann Bioscience Facilitated Genetics Arrive in Israel
Partner Facility Now Growing Canadian Cannabis StrainsVANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the "Company"
Isracann Bioscience Facilitates Cannabis Genetics Shipment to Israel
VANCOUVER, British Columbia, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the "Company"), a multi-faceted Israel-based company focused on bec
Isracann's Praesidio Expands Its Natural Health Products Distribution Network: Inks Deal With Pure Integrative Pharmacy
Isracann Biosciences Inc. (OTCPK:ISCNF) (CSE:IPOT) (XFRA:A2PT0E) a multi-faceted organization with a natural health medicine division (Praesidio Health) in Canada and holdings in Israel, has signed a
Praesidio Signs Distribution Agreement With Pure Integrative Pharmacy
VANCOUVER, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the "Company") a multi-faceted organization with a natural health m
Cannabis Company Isracann Biosciences Raises $234K In The First Tranche Of Private Placement
Isracann Biosciences Inc. (OTCPK:ISCNF) (CSE IPOT) (XFRA:A2PT0E) has closed the first tranche of its non-brokered private placement. The company issued 4.68 million units at a price of $0.05 per unit
Isracann Biosciences Announces Closing of First Tranche of $0.05 Unit Private Placement
VANCOUVER, British Columbia, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the "Company") is pleased to announce that it has closed the first t
Isracann Biosciences' Subsidiary Praesidio Health Submits NPNs To Health Canada
Praesidio Health, a wholly-owned subsidiary of Isracann Biosciences Inc. (OTCPK:ISCNF) (CSE:IPOT) (XFRA:A2PT0E), has completed the natural product number (NPN) submissions to Health Canada for its fir
Isracann Biosciences Subsidiary Praesidio Health Submits NPNs to Health Canada
VANCOUVER, British Columbia, May 19, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the "Company") a multi-faceted organization with a natural health med
Isracann Biosciences Acquires Praesidio Health And Appoints Natural Health Products Officers
Isracann Biosciences Inc. (OTCPK:ISCNF) (CSE:IPOT) (XFRA:A2PT0E) has closed its acquisition of Praesidio Health Inc. Pursuant to the definitive agreement dated March 24, 2022 with Praesidio and the sh
Isracann Biosciences acquires Praesidio Health and appoints products officers
Isracann Biosciences (OTCPK:ISCNF) has closed its acquisition of Praesidio Health by acquiring all of the issued and outstanding shares in the capital of Praesidio for aggregate consideration of C$4M,
Isracann Biosciences Acquires Natural Health Medicine Developer and Appoints Natural Health Products Officers
VANCOUVER, British Columbia, April 13, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the "Company") is pleased to announce that, further to the Company'
Isracann Biosciences Signs Definitive Agreement To Acquire Praesidio Health For $3.18M
Isracann Biosciences Inc. (OTCPK:ISCNF) (CSE:IPOT) (XFRA:A2PT0E) signed a definitive agreement dated March 24, 2022 with Praesidio Health Inc to acquire all of the issued and outstanding shares in the
Isracann Biosciences to acquire Canadian natural health medicine developer
Isracann Biosciences (OTCPK:ISCNF) will acquire all shares in the capital of Praesidio for aggregate consideration of C$4M in common shares of the company. Praesidio Health is an industry-leading, Ca
Isracann Biosciences Signs Definitive Agreement to Acquire Natural Health Medicine Developer
VANCOUVER, British Columbia, March 28, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the "Company") is pleased to announce that, further to the Company'
UPDATE - Isracann Signs LOI to Acquire Natural Health Medicine Developer
VANCOUVER, British Columbia, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the "Company" or "Isracann") a biosciences company focused on resear
Isracann To Acquire Natural Health Medicine Developer Praesidio Health For $3.14M
Isracann Biosciences Inc. (CSE:IPOT) (XFRA:A2PT0E) (OTC:ISCNF) has entered into a binding letter of intent to acquire Praesidio Health Inc. of Canada, a medical research company. Praesidio Health dev
Isracann to acquire natural health medicine developer
Isracann Biosciences (OTCPK:ISCNF) to acquire Praesidio Health of Canada. The appointment of Mr. Phil Floucault to the position of company's CEO in late October of 2021, allowed for a period of invest
No Data